Autoimmune Diseases  >>  tabalumab (LY2127399)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

9 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
tabalumab (LY2127399) / Eli Lilly
NCT01215942 / 2010-022208-36: An Open Label Study for Participants With Rheumatoid Arthritis

Terminated
3b
1086
Europe, Japan, US, RoW
LY2127399, Tabalumab
Eli Lilly and Company
Rheumatoid Arthritis
02/14
02/14
Illuminate-X , NCT01488708 / 2010-022101-18: On Open-Label Study in Participants With Systemic Lupus Erythematosus

Terminated
3b
1518
US
LY2127399, Placebo
Eli Lilly and Company
Systemic Lupus Erythematosus, Connective Tissue Disease, Autoimmune Disease
10/15
10/15
FLEX M, NCT01198002 / 2010-022205-17: A Rheumatoid Arthritis Study in Participants on a Background Treatment of Methotrexate

Terminated
3
1041
Europe, Japan, US, RoW
LY2127399, Placebo Q2W, Placebo Q4W, Methotrexate
Eli Lilly and Company
Rheumatoid Arthritis
12/12
01/14
FLEX O, NCT01202760 / 2010-022206-40: A Rheumatoid Arthritis Study in Participants

Checkmark Rheumatoid arthritis - ACR/ ARHP 2013
Sep 2013 - Sep 2013: Rheumatoid arthritis - ACR/ ARHP 2013
Completed
3
1004
Europe, Japan, US, RoW
LY2127399, Tabalumab, Placebo
Eli Lilly and Company
Rheumatoid Arthritis
12/12
07/13
FLEX V, NCT01202773 / 2010-022207-22: A Study in Participants With Rheumatoid Arthritis

Terminated
3
456
Europe, Japan, US, RoW
LY2127399, Placebo Q4W, Placebo Q2W
Eli Lilly and Company
Rheumatoid Arthritis
03/13
01/14
NCT01676701 / 2012-001618-40: Evaluation of Tabalumab Using Auto-Injector or Prefilled Syringe in Participants With Rheumatoid Arthritis (RA)

Terminated
3
8
US, Europe, RoW
Tabalumab Auto-Injector, LY2127399, Tabalumab Prefilled Syringe
Eli Lilly and Company
Rheumatoid Arthritis
08/13
08/13
NCT01196091 / 2010-022099-29: A Study of LY2127399 in Participants With Systemic Lupus Erythematosus

Checkmark For SLE
Oct 2014 - Oct 2014: For SLE
Completed
3
1164
Europe, Canada, Japan, US, RoW
LY2127399, Placebo every 2 weeks, Placebo every 4 weeks, Standard of Care, Non-steroidal anti-inflammatory drug, Corticosteroids, Antimalarials (used for SLE), Immunosuppressants
Eli Lilly and Company
Systemic Lupus Erythematosus, Connective Tissue Disease, Autoimmune Disease
07/14
06/15
NCT01205438 / 2010-022100-42: A Study of LY2127399 in Participants With Systemic Lupus Erythematosus

Checkmark For SLE
Oct 2014 - Oct 2014: For SLE
Completed
3
1124
Europe, Canada, US, RoW
LY2127399, Placebo every 2 weeks, Placebo every 4 weeks
Eli Lilly and Company
Systemic Lupus Erythematosus, Connective Tissue Disease, Autoimmune Disease
08/14
03/15
NCT02041091: A Study of Tabalumab (LY2127399) Using Two Different Injection Methods in Participants With Lupus

Terminated
3
226
US, RoW
Tabalumab Auto-Injector, LY2127399, Tabalumab Prefilled Syringe
Eli Lilly and Company
Lupus Erythematosus, Systemic
10/14
11/15

Download Options